Ocular Therapeutix (OCUL) Accumulated Expenses (2013 - 2026)

Ocular Therapeutix's Accumulated Expenses history runs 14 years deep, the most recent figure standing at $36.5 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 17.4% year-over-year to $36.5 million; the TTM figure through Mar 2026 stood at $36.5 million (up 17.4% YoY), while the FY2025 annual figure was $43.8 million, up 207.14% from the prior year.
• Accumulated Expenses was $36.5 million for Q1 2026 at Ocular Therapeutix, down from $43.8 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $43.8 million in Q4 2025 to a low of $5.4 million in Q1 2024.
• Historically, Accumulated Expenses has averaged $19.3 million across 5 years, with a median of $17.6 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses plunged 75.6% in 2024, then jumped 479.09% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $7.5 million in 2022, then increased by 8.62% to $8.2 million in 2023, then jumped by 74.99% to $14.3 million in 2024, then soared by 207.14% to $43.8 million in 2025, then fell by 16.76% to $36.5 million in 2026.
• The last three Accumulated Expenses figures came in at $36.5 million (Q1 2026), $43.8 million (Q4 2025), and $13.1 million (Q3 2025), per Business Quant data.